Oct 25, 2024

Featuring an interview with Dr Erika Hamilton, including the following topics:

• Pathophysiology and pharmacology of ER-positive breast cancer treatment (0:00)
• Clinical evidence available with oral selective estrogen receptor degraders (3:46)
• Mechanism of action of proteolysis-targeting chimeras (PROTACs) (13:22)
• PROTACs currently in clinical development (16:39)
• Case: A woman in her late 30s with HR-positive, HER2-negative metastatic breast cancer (mBC) experiencing progression on a CDK4/6 inhibitor (CDK4/6i) and an aromatase inhibitor (AI) (35:09)
• Case: A woman in her early 70s with HR-positive, HER2-negative mBC that progresses on a CDK4/6i and an AI (41:16)

CME information and select publications